
| Help Logout Interrupt | |
|--|--|
| Exercise the exercise of the e | |
| Main Menu Search Form Posting Counts Show S Numbers Edit S Numb | ers Preferences |
| | |
| V. '11. 1 | |
| Your wildcard search against 2000 terms has yielded the result Search for additional matches among the next 2000 terms | s below |
| THE PROCESSION AND A CONTROL OF A PROCESSION AND ADMINISTRATION ADMINISTRATION AND ADMINISTRATION ADMINISTRATION AND ADMINISTRA | nazione. Transaccione (il propositione del contraction que alcohe est |
| Search Results - | |
| Term | Documents |
| CTLA LIGHT DODD | 240 |
| CTLA.USPT,PGPB. | 240 |
| CTLACT.USPT,PGPB. CTLACT-ROUTINE.USPT,PGPB. | 4 |
| CTLACT-ROUTINE.USPT,PGPB. CTLADD.USPT,PGPB. | |
| CTLADD.USPT,PGPB. | |
| CTLADR/CT.USPT,PGPB. | |
| CTLAE.USPT,PGPB. | |
| CTLAI.USPT,PGPB. | |
| CTLAIG.USPT,PGPB. | 10 |
| CTL/MO.OSI 1,1 OT B. | 10 |
| TREAT\$(TREATMENT/POST).USPT,PGPB. | pickup term |
| ((CTLA\$) AND (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR | Prekap term |
| THERAP\$ OR ADMINIST\$)SAME(SCLEROSIS OR MULTIPLE | 81 |
| ADJ SCLEROSIS)).USPT,PGPB. | 1000 |
| There are more results than shown above. Click here to view the | entire set. |
| | 34 (1949) 14 (1949) 14 (1949) 14 (1949) 14 (1949) 14 (1949) 14 (1949) 14 (1949) 14 (1949) 14 (1949) 14 (1949) |
| US Patents Full-Text Database US Pre-Grant Publication Full-Text Database | |
| JPO Abstracts Database | |
| EPO Abstracts Database Derwent World Patents Index | |
| atabase: IBM Technical Disclosure Bulletins | |
| | |
| (ctla\$) and (treat\$ or inhibit\$ or suppress\$ or therap\$ or | Cloar : |
| Reine Search. administ\$)same(sclerosis or multiple adj | Clear |
| | STORY CONTRACTOR OF THE STORY O |
| Search History | |

Today's Date: 8/18/2001

| DB Name | Query | Hit Count | Set Name |
|-----------|---|-----------|-----------|
| USPT,PGPB | <pre>(ctla\$) and (treat\$ or inhibit\$ or suppress\$ or therap\$ or administ\$)same(sclerosis or multiple adj sclerosis)</pre> | 81 | <u>L4</u> |
| USPT,PGPB | (ctla\$) and (sclerosis or multiple adj sclerosis) | 98 | <u>L3</u> |
| USPT,PGPB | (ctla\$) same (sclerosis or multiple adj sclerosis) | 3 | <u>L2</u> |
| USPT,PGPB | (ctla\$) same (sclerosis or multiple adj sclerosis). clm. | 0 | <u>L1</u> |

2 of 2



Search Results -

| Term | Documents |
|---|-----------|
| CTLA\$ | 0 |
| CTLA.DWPI,EPAB,JPAB. | 67 |
| CTLACTLA.DWPI,EPAB,JPAB. | 1 |
| CTLACTLAC.DWPI,EPAB,JPAB. | 1 |
| CTLACTLACTLBCTLB.DWPI,EPAB,JPAB. | 1 |
| CTLADR.DWPI,EPAB,JPAB. | 1 |
| CTLAMP.DWPI,EPAB,JPAB. | 1 |
| CTLAN.DWPI,EPAB,JPAB. | 6 |
| CTLA4.DWPI,EPAB,JPAB. | 62 |
| CTLA4IG.DWPI,EPAB,JPAB. | 8 |
| ((CTLA\$) AND (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR THERAP\$ OR ADMINIST\$)SAME(SCLEROSIS OR MULTIPLE ADJ SCLEROSIS)).JPAB,EPAB,DWPI. | 14 |

There are more results than shown above. Click here to view the entire set.

| | US Patents Full-Text Database US Pre-Grant Publication Full-Text Database | |
|-------|---|---|
| | JPO Abstracts Database EPO Abstracts Database | |
| base: | Derwent World Patents Index IBM Technical Disclosure Bulletins | - |

Database: IBM Technical Disclosure Bulletins

| : | (ctla\$) and (treat\$ or inhibit\$ or | | |
|----------------|--|---|---------------------------------------|
| Refine Search: | <pre>suppress\$ or therap\$ or administ\$)same(sclerosis or multiple adj</pre> | F | Clear |
| | | | Books and additional condition of the |

Search History

Today's Date: 8/18/2001

| DB Name | Query | Hit Count | Set Name |
|----------------|--|-----------|-----------|
| JPAB,EPAB,DWPI | (ctla\$) and (treat\$ or inhibit\$ or suppress\$ or therap\$ or administ\$)same(sclerosis or multiple adj sclerosis) | 14 | <u>L5</u> |
| USPT,PGPB | (ctla\$) and (treat\$ or inhibit\$ or suppress\$ or therap\$ or administ\$)same(sclerosis or multiple adj sclerosis) | 81 | <u>L4</u> |
| USPT,PGPB | (ctla\$) and (sclerosis or multiple adj sclerosis) | 98 | <u>L3</u> |
| USPT,PGPB | (ctla\$) same (sclerosis or multiple adj sclerosis) | 3 | <u>L2</u> |
| USPT,PGPB | (ctla\$) same (sclerosis or multiple adj sclerosis). clm. | 0 | <u>L1</u> |

| 20/2/2025 | 120 g 1.22 | W | EST | \$425.000/2015\$Vel\$4.5200 | 24.0 20.77.00.7 Dec. 123 |
|-----------|-------------|--|--|-----------------------------|--------------------------|
| | | Help Lo | gout Interru | pt | |
| | Amelijan | постания принципалний в в постанов пост | The second secon | 3000 saarna40 XXXXIII | |
| Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences |
| | | | | | |

Search Results -

| Term | Documents |
|---|-----------|
| CTLA\$ | 0 |
| CTLA.DWPI,EPAB,JPAB. | 67 |
| CTLACTLA.DWPI,EPAB,JPAB. | 1 |
| CTLACTLAC.DWPI,EPAB,JPAB. | 1 |
| CTLACTLACTLBCTLB.DWPI,EPAB,JPAB. | 1 |
| CTLADR.DWPI,EPAB,JPAB. | 1 |
| CTLAMP.DWPI,EPAB,JPAB. | 1 |
| CTLAN.DWPI,EPAB,JPAB. | 6 |
| CTLA4.DWPI,EPAB,JPAB. | 62 |
| CTLA4IG.DWPI,EPAB,JPAB. | 8 |
| ((CTLA\$) AND (TREAT\$ OR INHIBIT\$ OR SUPPRESS\$ OR THERAP\$ OR ADMINIST\$)SAME(SCLEROSIS OR MULTIPLE ADJ SCLEROSIS)).JPAB,EPAB,DWPI. | 14 |

There are more results than shown above. Click here to view the entire set.

| | US Patents Full-Text Database US Pre-Grant Publication Full-Text Database | |
|-----------|---|--------|
| | JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index | |
| Database: | IBM Technical Disclosure Bulletins | \Box |

| Refine Search: | (ctla\$) and (treat\$ or inhibit\$ or suppress\$ or therap\$ or administ\$)same(sclerosis or multiple adj Clear |
|----------------|---|
| | |

Search History

Today's Date: 8/18/2001

| DB Name | Query | Hit Count | Set Name |
|----------------|--|-----------|-----------|
| JPAB,EPAB,DWPI | (ctla\$) and (treat\$ or inhibit\$ or suppress\$ or therap\$ or administ\$)same(sclerosis or multiple adj sclerosis) | 14 | <u>L5</u> |
| USPT,PGPB | (ctla\$) and (treat\$ or inhibit\$ or suppress\$ or therap\$ or administ\$)same(sclerosis or multiple adj sclerosis) | 81 | <u>L4</u> |
| USPT,PGPB | (ctla\$) and (sclerosis or multiple adj sclerosis) | 98 | <u>L3</u> |
| USPT,PGPB | (ctla\$) same (sclerosis or multiple adj sclerosis) | 3 | <u>L2</u> |
| USPT,PGPB | (ctla\$) same (sclerosis or multiple adj sclerosis). clm. | 0 | <u>L1</u> |

```
(Item 7 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
  123081061
               CA: 123(7)81061d
                                   JOURNAL
  Role of CD80 (B7-1) and CD86 (B7-2, B70) in T cell activation
  AUTHOR(S): Ebata, Tomohiko; Azuma, Miyuki
  LOCATION: Sch. Med., Juntendo Univ., Tokyo, Japan, 113
  JOURNAL: Mol. Med. (Tokyo) DATE: 1995 VOLUME: 32 NUMBER: Suppl. 428
  PAGES: 22-9 CODEN: MOLMEL ISSN: 0918-6557 LANGUAGE: Japanese
  SECTION:
CA215000 Immunochemistry
  IDENTIFIERS: CD80 CD86 T lymphocyte signaling review, B71 B72 T
lymphocyte signaling review
  DESCRIPTORS:
Antigens, B70... Antigens, B7/BB-1... Lymphocyte, T-cell... Signal
transduction, biological...
    B7-1 and B7-2 antigens role in T-cell signaling
 6/7/57
            (Item 8 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
  123081035
               CA: 123(7)81035y
                                   JOURNAL
  Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper
cell differentiation?
  AUTHOR(S): Thompson, Craig B.
  LOCATION: Howard Hughes Medical Inst., Univ. Chicago, Chicago, IL, 60637,
  JOURNAL: Cell (Cambridge, Mass.) DATE: 1995 VOLUME: 81 NUMBER: 7
  PAGES: 979-82 CODEN: CELLB5 ISSN: 0092-8674 LANGUAGE: English
  SECTION:
CA215000 Immunochemistry
  IDENTIFIERS: review B71 B72 T cell differentiation
  DESCRIPTORS:
Antigens, B70... Hematopoiesis, T-cell lymphopoiesis... Lymphocyte, T-cell,
helper cell...
    distinct roles for B7-1 and B7-2 in T helper cell differentiation
Antigens, B7/BB-1...
    Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper
    cell differentiation
 6/7/58
            (Item 9 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
  122130384
               CA: 122(11)130384b
                                     JOURNAL
  Functional role of CD86 (B70/B7-2) on T cell activation
  AUTHOR(S): Ito, Daisuke; Azuma, Miyuki
  LOCATION: Juntendo Univ., Tokyo, Japan, 113
  JOURNAL: Immunol. Front. DATE: 1994
                                       VOLUME: 4 NUMBER: 6 PAGES: 541-4
  CODEN: IMFREG ISSN: 0917-0774 LANGUAGE: Japanese
  SECTION:
CA215000 Immunochemistry
  IDENTIFIERS: CD86 antigen structure function review, T lymphocyte CD86
antigen review
  DESCRIPTORS:
```

```
Lymphocyte, T-cell...
    B7-2 antigen in activation of
Antigens, B70...
    in T-cell activation
            (Item 10 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
              CA: 121(17)202514y
                                      JOURNAL
  B70 (B7-2), a second ligand for CD28 and CTLA-4
  AUTHOR(S): Ito, Daisuke; Azuma, Miyuki
  LOCATION: Fac. Med., Univ. Tokyo, Tokyo, Japan, 113
  JOURNAL: Jikken Igaku DATE: 1994 VOLUME: 12 NUMBER: 12 PAGES: 1551-5
  CODEN: JIIGEF ISSN: 0288-5514 LANGUAGE: Japanese
  SECTION:
CA215000 Immunochemistry
  IDENTIFIERS: review \overline{\text{B70}} CD28 CTLA4 antigen ligand
  DESCRIPTORS:
Antigens, B70... Antigens, CD28... Proteins, specific or class, CTLA-4...
    B70 antigen as ligand for CD28 and CTLA-4
Connection closed by remote host
```

6/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11669616 BIOSIS NO.: 199800451347

Targeting the B7 /CD28: CTLA-4 costimulatory system in CNS autoimmune disease.

AUTHOR: Karandikar Nitin J; Vanderlugt Carol L; Bluestone Jeffrey A; Miller Stephen D(a)

AUTHOR ADDRESS: (a) Dep. Microbiol.-Immunol. Interdepartmental Immunobiol.

Cent., North Western Univ. Med. Sch., 303**USA

JOURNAL: Journal of Neuroimmunology 89 (1-2):p10-18 Aug. 14, 1998

ISSN: 0165-5728

DOCUMENT TYPE: Literature Review

RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: The B7/CD28:CTLA-4 costimulatory pathway plays a critical role in determining the fate of immune responses (activation vs. down-regulation) and is a highly promising therapeutic target for treating autoimmune diseases. In this review, we highlight the mechanisms by which this costimulatory pathway operates emphasizing the role of the different components in the pathogenesis of relapsing experimental autoimmune encephalomyelitis, a CD4 T cell-mediated autoimmune model of multiple sclerosis. The separate and distinct roles of B7-1, B7-2 and CTLA-4 in positive and negative regulation of autoimmune pathogenesis are

6/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11995577 BIOSIS NO.: 199900276096

CD28/CTLA-4 and CD80/CD86 families: Signaling and function.

AUTHOR: Slavik Jacqueline M; Hutchcroft Jill E; Bierer Barbara E(a)

AUTHOR ADDRESS: (a) National Heart, Lung, and Blood Ins., 10 Center Drive,

Bldg. 10, Room 5D49, Bethesda, MD, 20892**USA

JOURNAL: Immunologic Research 19 (1):p1-24 Feb., 1999

ISSN: 0257-277X

DOCUMENT TYPE: Literature Review

RECORD TYPE: Abstract LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: T cell stimulation in the absence of a second, costimulatory signal can lead to anergy or the induction of cell death. CD28 is a major T cell costimulatory receptor, the coengagement of which can prevent anergy and cell death. The CD28 receptor is a member of a complex family of polypeptides that includes at least two receptors and two ligands. Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is the second member of the CD28 receptor family. The ligands or counterreceptors for these two proteins are the B7 family members, CD80 (B7-1) and CD86 (B7-2). This article reviews the CD28/CTLA4 and CD80/CD86 families, and outlines the functional outcomes and biochemical signaling pathways recruited after CD28 ligation.